Your session is about to expire
← Back to Search
CAR T-cell Therapy
KT-253 for Cancer
Phase 1
Waitlist Available
Research Sponsored by Kymera Therapeutics, Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up from baseline scan until first documented progression or death from any cause, whichever comes first, about 18 months
Awards & highlights
No Placebo-Only Group
Summary
This trial will study the safety and effectiveness of KT-253 to treat relapsed and advanced cancers, such as leukemia, lymphoma, and solid tumors.
Who is the study for?
This trial is for adults with certain advanced cancers like high grade myeloid malignancies, ALL, lymphoma, and solid tumors that have not responded to standard treatments. Participants must be in fairly good physical condition (ECOG 0-2), have recovered from previous therapies, and should not have had major surgery or cancer therapy too close to the start of the study.
What is being tested?
KT-253 is being tested in this Phase 1 trial to determine its safety and effectiveness for treating various relapsed/refractory cancers. The study aims to find the best dose based on how patients react and any signs of improvement in their conditions.
What are the potential side effects?
While specific side effects are not listed here, typical ones may include reactions at the infusion site, fatigue, nausea, changes in blood counts leading to increased infection risk or bleeding tendencies. Side effects will be closely monitored throughout the trial.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ from baseline scan until first documented progression or death from any cause, whichever comes first, about 18 months
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~from baseline scan until first documented progression or death from any cause, whichever comes first, about 18 months
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
Incidence and severity of adverse events
Maximum Tolerated Dose (MTD) and recommended Phase 2 dose (RP2D) in Patients
Secondary study objectives
Area under the Plasma Concentration versus Time Curve (AUC) of KT-253
Duration of Response (DoR) in Patients Treated with KT-253
Evidence of Clinical Activity of KT-253 in ALL patients
+7 moreAwards & Highlights
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Trial Design
2Treatment groups
Experimental Treatment
Group I: Phase 1 Dose Escalation Arm B in patients with R/R High Grade Myeloid Malignancies and ALLExperimental Treatment1 Intervention
KT-253 dosed IV once every three weeks in 21-day cycles
Group II: Phase 1 Dose Escalation Arm A in patients with R/R Solid Tumors and LymphomasExperimental Treatment1 Intervention
KT-253 dosed intravenous (IV) once every three weeks in 21-day cycles
Find a Location
Who is running the clinical trial?
Kymera Therapeutics, Inc.Lead Sponsor
7 Previous Clinical Trials
870 Total Patients Enrolled
Ashwin Gollerkeri, MDStudy DirectorKymera Therapeutics, Inc.
4 Previous Clinical Trials
354 Total Patients Enrolled
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:- My tumor has a p53 mutation.My heart condition is stable.I have advanced blood cancer and no recent severe graft versus host disease.I have advanced leukemia and signs of it in my brain or spinal cord.My cancer is a solid tumor or lymphoma, confirmed by lab tests.I haven't had chemotherapy or radiation in the last 2 weeks.I have been cancer-free for at least 2 years if I had another type of cancer.My organs are working well.I can take care of myself and am up and about more than half of the day.I have active brain metastases that are not under control or causing symptoms.My leukemia or myeloid disease has not responded to standard treatments.My cancer has not responded to at least two treatments or there are no standard treatments available for it.I had a stem cell transplant within the last 6 months or my lymphoma worsened within 6 months after the transplant.I haven't had cancer treatment or experimental drugs in the last 2 to 4 weeks.I have not had major surgery within the last 4 weeks.I had a stem cell transplant less than 12 weeks ago or a donor immune cell infusion without special preparation less than 4 weeks ago.I had a stem cell transplant less than 4 weeks ago or haven't recovered from its side effects.My side effects from previous treatments are mild or gone, except for hair loss and some nerve pain.I have advanced blood cancer and received a special immune therapy less than 3 weeks ago.
Research Study Groups:
This trial has the following groups:- Group 1: Phase 1 Dose Escalation Arm A in patients with R/R Solid Tumors and Lymphomas
- Group 2: Phase 1 Dose Escalation Arm B in patients with R/R High Grade Myeloid Malignancies and ALL
Awards:
This trial has 1 awards, including:- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
Timeline:
This trial has the following timeline:- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Other Trials to Consider
Popular Categories
Learn More About These Treatments
Share this study with friends
Copy Link
Messenger